How much time does the medtech industry need to comply with a final version of the US Food and Drug Administration’s Quality Management System Regulation? Well, if you read many of the 69 comments to date from stakeholders on the draft QMSR, you’d think the answer is two to three years.
Expert: Granting More Than 1 Year To Comply With QMSR Rule Puts FDA In A Pickle
US Regulatory Roundup, May 2022
Many commenters on the US FDA’s draft Quality Management System Regulation want two or three years to comply, but one medtech expert says that length of time could put the agency in a difficult position. Our coverage of the FDA’s draft QMSR – and an array of other news and analysis – topped our list of most-read Medtech Insight stories in May.
More from Regulation
• By
The US FDA has published its final document to guide sponsors on using sex-specific data in designing clinical trials of medical devices. However, the guidance removes all references to gender that appeared in January’s draft guidance, released before the Trump administration took office.
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
• By
A seemingly humorous social media post on April Fool’s Day struck a nerve with regulatory experts, reflecting real concerns about recent actions by the US Food and Drug Administration.
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
More from Policy & Regulation
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
• By
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.
• By
Swiss medtech exporters seek urgent diplomatic action from the Swiss Federal Council in a bid to overturn the 2 April US decision to put tariffs on goods imports.